BGM Group Ltd. (BGM)
NEGATIVEFundamental
~22
मूल्य
$0.25
मार्केट कैप
$100M
भाग 1 · कंपनी का मूल्य कितना है
अवलोकन
BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline active pharmaceutical ingredients, which are used by pharmaceutical companies in the manufacturing of medications that use oxytetracycline as an active ingredient. The company also provides licorice products, such as Gan Di Xin, a antitussive and expectorant medicine made from raw licorice materials; Qilian Shan licorice extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, an ingredient for medical preparation companies to produce compound licorice oral solutions. In addition, it offers traditional Chinese medicine derivatives products comprising Ahan antibacterial paste that is used to treat refractory chronic skin diseases; heparin products, including heparin sodium preparation, an ingredient for pharmaceutical companies to produce medications used in treating cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and sausage casings, such as Zhu Xiaochang sausage casings for culinary purposes. Further, the company provides Fertilizer products comprising Xiongguan organic fertilizers to improve crop yield, increase soil's chemical properties, and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers for plant growth. Additionally, it focuses on the AI-driven commercialization of DuXiaoBao platform to provide comprehensive and professional AI solutions and intelligent robot services for insurance companies, insurance brokers, and consumers. BGM Group Ltd. is based in Chengdu, China.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
सीमित वित्तीय डेटा उपलब्ध है (37% मेट्रिक्स)। स्कोर इस कंपनी के fundamentals को सटीक रूप से प्रतिबिंबित नहीं कर सकते।
बैलेंस शीट और तरलता
राजस्व
$74M
शुद्ध आय
$-39M
Free Cash Flow
-
कुल इक्विटी
$742M
कुल देनदारियाँ
-
Current Ratio
1.24
Interest Coverage
-
Debt/EBITDA
-
Earnings Per Share
राजस्व और शुद्ध आय
Free Cash Flow
आय विवरण
ऐतिहासिक विवरण
समय के साथ मार्जिन
समय के साथ ऋण
ऋण कितना भारी है
वृद्धि तालिका
वृद्धि — राजस्व
Fair Value अनुमान
Fair Value
$0.10
वर्तमान मूल्य
$0.25
Margin of Safety
-154.5%
Fair Value सीमा
$0.08 - $0.13
अनुमान विधियाँ
मूल्यांकन मेट्रिक्स
P/E Ratio
-
ROE
-7.0%
P/B Ratio
0.15
P/FCF
31.32
Gross Margin
16.6%
ROIC
-1.8%
लाभप्रदता Radar
Value Creation (Economic Moat)
ROIC
-1.8%
WACC
14.5%
ROIC − WACC
-16.2 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental विश्लेषण मानदंड
पास (2)
- P/B Ratio 0.15
- Current Ratio
फेल (8)
- Price CAGR -54.38%
- ROIC -1.8%
- Gross Margin 16.6%
- P/FCF 31.32
- DCF valuation (Overvalued)
- ROE -7.0%
- Revenue Growth 5Y -5.4%
- Piotroski F-Score 0/9
अनुपलब्ध (17)
- EPS data insufficient
- Dividend Payout NaN%
- Debt/Equity ratio
- Operating Margin NaN%
- Positive Free Cash Flow
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- Price below Graham Number
- Analyst Consensus (Finnhub)
- Earnings Surprise (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
- Share Dilution (need 2+ years)
- Net Margin Trend (invalid data)
Piotroski F-Score
गंभीर वित्तीय चिंताएं
Earnings गुणवत्ता
निम्न गुणवत्ता: accounting की जांच करें
शेयर Dilution
शेयर वापस खरीद रही है। शेयरधारक अनुकूल
प्रशासन
कार्यकारी टीम
| नाम | पद | आयु |
|---|---|---|
| Ms. Huandi Zhao | Co-Chief Executive Officer & Director | 40 |
| Ms. Li Hong | Co-Chief Executive Officer | - |
| Ms. Yaxuan Zhai | Chief Financial Officer | 30 |
भाग 2 · कीमत और खरीदने का समय
यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।
Latest News
Recent headlines for BGM, sourced from Markets Gazette.